U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

Yang‐Min Ning(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Lijun Zhang(Center for Drug Evaluation and Research), Michael H. Brave(United States Food and Drug Administration), V. Ellen Maher(United States Food and Drug Administration), Geoffrey Kim(United States Food and Drug Administration), Rajeshwari Sridhara(Center for Drug Evaluation and Research), Shenghui Tang(United States Food and Drug Administration), Amna Ibrahim(Beni-Suef University)
The Oncologist
June 12, 2015
10.1634/theoncologist.2015-0166
Cited by 42

Related Papers

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
|The Oncologist|2018|880
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
|PubMed|2001|861